Biontech is relocating part of its research to Great Britain in the future. Concerns about the company moving away are unfounded. The announcement is nevertheless a warning sign – for Germany as a research location.
A few days ago, the vaccine company Biontech posted a photo from London on their social media channels. It shows company founders Ugur Sahin and Özlem Türeci together with their chief financial officer, Sean Marett, who was born in Britain. The three laugh and hug in front of 10 Downing Street, the seat of the Prime Minister. The photo was taken in July, but fits in well with the Mainz-based company’s latest plans: Biontech will set up a center for research and development of new types of cancer drugs in Great Britain, and the company has signed an agreement with the British government on this.